Clinical Consultations™: Evolving Paradigms for the Management of Chronic Kidney Disease and Cardiovascular Comorbidities
April 26, 2022
April 26, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward nephrologists, cardiologists, primary care providers, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with CKD.
Type 2 diabetes (T2D) is a leading cause of morbidity and mortality worldwide, and it is estimated that 9.3% of the global population is affected by this condition. Diabetic kidney disease (DKD) is a disease multiplier that increases the risk of stroke, cardiac and vascular disease. It affects up to 40% of patients with diabetes during their lifespan, exposing them to a 3-fold higher risk of cardiovascular (CV) death compared with those with diabetes alone. In fact, patients with DKD are far more likely to die from cardiovascular disease (CVD) than to progress to end-stage renal disease (ESRD). Not surprisingly, this burden of complications and comorbidity translates to poor quality of life (QoL) and substantially higher health care resource utilization and costs.
During this Clinical Consultations™ program, 2 expert faculty discuss the importance of screening patients with chronic kidney disease (CKD) for comorbidities and treating them early. They also discuss the treatment options available among both current and emerging classes of therapies and across different clinical subspecialties.
Upon completion of this activity, participants should be better able to:
- Summarize current guideline recommendations regarding testing for CKD in at-risk patients with T2D
- Discuss clinical trial evidence regarding therapies for patients with CKD and CV comorbidities
- Develop treatment plans for patients with CKD and CV comorbidities based on current evidence and patient presentation
Eden Miller, DO
High Lakes Health Care Sisters
Kim Zuber, PA-C
American Academy of Nephrology Physician Assistants
St. Petersburg, FL
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Eden Miller, DO
- Grant/Research Support: Abbott, Pendulum
- Speaker’s Bureau: Eli Lilly and Company, Nova Pharma, Boehringer Ingelheim, Abbott, Bayer
Kim Zuber, PA-C, has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.